Code Pharma's GAMMORA Shows Promise in Targeting and Eliminating HIV-Infected Cells
Key Insights
Code Pharma (search) will present early-stage clinical trial results of GAMMORA (search), a novel HIV (search) treatment, at the HIV Drug Therapy 2024 Conference in Glasgow.
GAMMORA (search) induces self-destruction of HIV (search)-infected cells, potentially offering a cure rather than lifelong management, unlike traditional antiretroviral therapies.
The drug's precision targeting ensures the elimination of infected cells while leaving healthy CD4 cells intact, showing drastic viral load reduction without harmful side effects.
Code Pharma (search) is preparing to present findings from clinical trials of its HIV (search) drug, GAMMORA (search), at upcoming international conferences. The presentations will take place at the HIV Drug Therapy 2024 Conference in Glasgow in November 2024, and at the HIV Persistence During Therapy Workshop in Miami, Florida in December 2024.
GAMMORA's Novel Mechanism of Action
GAMMORA (search) represents a new approach to HIV (search) treatment. Unlike current antiretroviral therapies that control the virus by inhibiting its activity, GAMMORA targets and eliminates HIV-infected cells. This is achieved by inducing self-destruction of these cells, which allows the immune system to regenerate healthy CD4 cells. The drug is a synthetic peptide derived from HIV-1 integrase (search), initially identified at the Hebrew University of Jerusalem, Israel. By inducing the viral integration process, GAMMORA pushes HIV-infected cells into self-destruction.
Early clinical trials have indicated that GAMMORA (search) can significantly reduce the HIV (search) viral load without causing harmful side effects. The drug's precision targeting ensures that only infected cells are eliminated, leaving healthy cells intact. This mechanism offers the potential for a cure, contrasting with the lifelong management of HIV as a chronic condition required by current treatments.
Code Pharma's Focus on Peptide-Based Therapies
Code Pharma (search), headquartered in the Netherlands with R&D operations in Israel, specializes in developing cost-effective, peptide-based treatments for infectious diseases and cancer. The company collaborates with an international team of experts in peptide chemistry, cell culture, and clinical development. Code Pharma aims to deliver therapies that address unmet medical needs and improve patient outcomes globally.